

NOTICE TO THE BAR

MULTICOUNTY LITIGATION APPLICATION – NEW JERSEY STATE COURT LITIGATION INVOLVING ELMIRON®

The Supreme Court has received an application pursuant to Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," requesting Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Research & Development, LLC, Janssen Ortho, LLC, and Ortho-McNeil Pharmaceuticals, LLC alleging injuries as a result of the use of the prescription medication Elmiron®. Elmiron® is a brand-name prescription drug prescribed to patients suffering from Interstitial Cystitis, a chronic medical condition that causes bladder pressure and pain.


The MCL application was submitted by counsel for plaintiffs.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **October 10, 2021** to:

Hon. Glenn A. Grant
Acting Administrative Director of the Courts
Attention: MCL Application – Elmiron®
Hughes Justice Complex, P.O. Box 037
Trenton, New Jersey 08625-0037

Comments/objections may also be submitted by email to Comments.mailbox@njcourts.gov.

A copy of the application submitted to the Court is posted with this Notice on the Judiciary's Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center <https://www.njcourts.gov/attorneys/mcl/index.html>.

A handwritten signature in black ink, appearing to read "Glenn A. Grant", is written over a horizontal line.

Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: September 7, 2021